Focal Therapy for Localised Prostate Cancer Using Irreversible Electroporation

Inclusion Criteria: * Histologically proven prostate cancer, Gleason Score \</=7 * An anterior visible lesion on mpMRI, that is accessible to IRE treatment * Transperineal prostate biopsies (template mapping and/or limited targeted) correlating with clinically significant lesion in the area of the MR-visible lesion (within 2 Barzell zones) * Absence of clinically significant disease outside of the planned treatment zone, from histopathology and/or mpMRI findings * Stage radiologicalT1-T2cN0M0 disease, as determined by local guidelines * Serum PSA \</=15 ng/ml * Life expectancy of \>/= 10 years * Signed informed consent by patient * An understanding of the English language sufficient to understand written and verbal information about the trial and consent process Exclusion Criteria: * Men who have had previous radiation therapy * Men who have had androgen suppression/hormone treatment within the previous 12 months for their prostate cancer * Men with evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging * Men with a non-visible tumour on mpMRI * Men with an inability to tolerate a transrectal ultrasound * Men with latex allergies * Men who have undergone prior significant rectal surgery preventing insertion of the TRUS probe (decided on the type of surgery in individual cases) * Men who have had previous IRE, HIFU, cryosurgery, thermal or microwave therapy to the prostate. * Men who have undergone a Transurethral Resection of the Prostate (TURP) for symptomatic lower urinary tract symptoms within 6 months. These patients may be included within the trial if deferred from consenting and screening until at least 6 months following the TURP. * Men not fit for major surgery as assessed by a Consultant Anaesthetist * Men unable to have pelvic MRI scanning (severe claustrophobia, permanent cardiac pacemaker, metallic implant etc likely to contribute significant artefact to images) * Presence of metal implants/stents in the urethra * Men with renal impairment with a GFR of \<35ml/min (unable to tolerate Gadolinium dynamic contrast enhanced MRI).